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Abstract: The pemphigus group comprises the autoimmune intraepidermal blistering diseases classically divid-
ed into two major types: pemphigus vulgaris and pemphigus foliaceous. Pemphigus herpetiformis, IgA pemphi-
gus, paraneoplastic pemphigus and IgG/IgA pemphigus are rarer forms that present some clinical, histological
and immunopathological characteristics that are different from the classical types. These are reviewed in this arti-
cle. Future research may help definitively to locate the position of these forms in the pemphigus group, especial-
ly with regard to pemphigus herpetiformis and the IgG/ IgA pemphigus.
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INTRODUCTION
Pemphigus is a group of life-threatening
autoimmune intraepidermal blistering diseases
caused by immunoglobulins directed against ker-
atinocyte cell surface components and histologically
characterized by acantholysis. Classically there are
two major types of pemphigus: vulgaris (PV) and foli-
aceous (PF), in which IgG autoantibodies recognize
desmossomal components desmoglein-3 (Dsg-3) and
desmoglein-1 (Dsg-1) respectively.1-3
Since 1975 rare forms of pemphigus have how-
ever been described, presenting clinical, histological
and immunopathological aspects that differentiate
them from the classical vulgaris and foliaceus variants.4
This article reviews the current knowledge
about these non-classical variants of pemphigus.
PEMPHIGUS HERPETIFORMIS
Since 1955, before immunological studies were
available, there were a number of reports that clinical-
ly resembled dermatitis herpetiformis (DH) in
patients, but which showed histological features of
pemphigus with acantholysis.5-7 Other cases were later
described, which showed circulating and in vivo
bound pemphigus antibodies.8-10 In 1975, Jablonska et
al.11 described a similar case and proposed the name
pemphigus herpetiformis (PH). These authors
believed that it was a variant of pemphigus having a
long course, with early atypical clinical and histologi-
cal features, that could evolve into typical pemphigus
if the patient did not receive appropriate treatment. In
1987, a review of 205 cases of pemphigus found 15
(7.3%) cases that were classified as PH, five of which
also presented features of PF.12 In 1996 Santi et al.
described seven cases of PH that showed features of
PF, or had disease that evolved into classic PF (five),
fogo selvagem (FS) (one) and PV (two), and all of them
presented antiepidermal autoantibodies that recog-
nized Dsg-1.13 This was the first recognized PH anti-
gen.13-15 Later, some reports also found antibodies
against Dsg-3 or both DSg-1 and 3 and, more recently,
desmocollin-1(Dsc-1) desmocollin-3 (Dsc-3)  and an
unknown 178-kDa protein.16-20
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At present there seems to be some consensus on
whether PH is a distinct entity, and most authors con-
sider it to be different from the classic pemphigus
variants because of its clinical peculiarity and benign
course.4,18-27 However, others have described it as a
variant of PF or PV, given the fact that several patients
with PH show features of or may evolve into having
PF or PV, besides frequently presenting the same tar-
get cell surface antigens.13,15 A recent study  that has
analyzed the Dsg-1 and Dsg-3 epitopes recognized by
serum samples from cases of mucosal dominant-type
PV and mucocutaneous-type PV over the disease
course, also studied sera from 19 PH patients and 14
PNP cases, finding that PNP and PH show broader
epitope distribution compared with the classical pem-
phigus.25 This study concluded that the different
autoantibody profiles between these diseases and PV
may contribute to their unique clinic and histopatho-
logical characteristics.
DEFINITION AND EPIDEMIOLOGY
PH is characterized by clinical features that
resemble DH and immunological and histological find-
ings consistent with pemphigus. It is a rare pemphigus
type, accounting for 6-7% of cases in some studies, that
equally affects men and women, aged 31 to 83
years, with rare case reports during childhood.21,28-31
CLINICAL FEATURES
Patients with PH are rarely thought to have this
diagnosis when they first seek medical care. Clinical
presentation is usually atypical, and other diagnoses
can be hypothesized, such as DH, bullous pem-
phigoid and linear IgA bullous dermatosis.12 Patients
usually show erythematous, gyrate, annular and ede-
matous lesions, with clusters of small or abortive vesi-
cles and/ or pustules, frequently in herpetiform pat-
tern (Figure 1).11 These features are not generally seen
in PF and PV.21 Mucous lesions are not a frequent
issue, but can be present in some patients. Pruritus is
frequently associated and might be severe.4,11 Some
patients can show eosinophilia in the blood.12,32 PH can
sometimes evolve into the classical forms of pemphi-
gus (PV and PF).4 The opposite has also been
described in the literature.11,33 Other cases can be ini-
tially misdiagnosed as other immunobullous diseases
or as the classic variants of pemphigus, such as in one
of the four PH patients of our outpatient clinic, who
was initially thought to have PF due to the histopatho-
logic and DIF results (Maehara L de S, et al. unpub-
lished data). This female patient evolved years later
with pruritic edematous plaques, with grouped vesi-
cles and tense blisters. The histological exam and DIF
revealed interstitial edema, vascular ecstasy and epi-
dermal exocytosis of neutrophils and eosinophils,
with intercellular deposits of IgG and C3.
FIGURE 1: Pemphigus herpetifor-
mis: (A) patient presenting grou-
ped vesicles, blisters, erosions
and crusts onto an erythematous
skin in a herpetiform pattern on
her forearms; (B) similar lesions
on her buttocks and back; (C) the
same patient 10 days after pulse
therapy with methylprednisolo-
ne (1 g/day for 3 days), showing
a good clinical response; (D) his-
topathological exam of a forearm
lesion showing suprabasal blister
containing some acantholytic
cels, neutrophils and eosinophils,
besides focal eosinophilic spon-
giosis (HE 400x); (E) DIF of peri-
lesional skin showing intercellu-
lar distribution of IgG and C3
throughout the entire epidermis
A B
D
C
E
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HISTOPATHOLOGY
The histological findings can vary among
patients and one patient can present different histo-
logical features at different times or biopsies. More
than one biopsy may therefore be necessary for diag-
nosis of PH.11,12,34 Subcorneal pustules and/ or intraepi-
dermal vesicles filled with neutrophils and /or
eosinophils and neutrophilic and/ or eosinophilic
spongiosis have already been described in those cases
(Figure 1). Acantholysis may be minimal or
absent.4,35 Although this variant differs histologically
from PF and PV due to these characteristic findings,
the histologic patterns are widely heterogeneous:
ranging from those with only spongiosis and inflam-
matory cells exocitosis to typical acantholysis.
IMMUNO-PATHOGENESIS
DIF is the same as the classic forms of pemphi-
gus: intercellular deposits of IgG and C3 in the epider-
mis (Figure 1). Indirect immunofluorescence (IIF),
enzyme-linked immunosorbent assay (ELISA) or
immunoblotting can show circulating antibodies
against epidermal components, usually Dsg-1,  and
less commonly Dsg-3 , Dsc 1 and 3 and an unknown
178-kDa protein.13-20 Although most cases show the
same target antigens of the classic variants of pemphi-
gus the consequences of the antibody binding are
probably different, as PH autoantibodies may recog-
nize functionally less important epitopes of Dsg-1 or 3
and therefore do not lead directly to acantholysis. It is
thought that autoantibodies in PH may induce signal-
ing pathway of cytokines (IL-8) production by ker-
atinocytes that attract inflammatory cells to the tissue,
with focal intercellular edema and eosinophilic spon-
giosis.36,37 Another recent study may favor this hypoth-
esis since it was found that that PH sera showed a
broader epitope distribution compared with PV,
which may contribute to its characteristic clinico-
histopathological features.25
ASSOCIATIONS
Some diseases have been described together
with PH, such as psoriasis, thyroid diseases, systemic
lupus erythematosus, HIV infection and malignan-
cies: lung cancer, esophageal carcinoma, prostatic can-
cer  and cutaneous angiosarcoma.20,22,23,38-46 Some
authors suggest the name paraneoplasic pemphigus
herpetiformis, because of the parallel course of both
diseases. However, IIF in rat bladder has not been
evaluated by those reports and only two of them
searched for the known paraneoplasic pemphigus
antigens by immunoblotting.22,45
TREATMENT
PH usually has an indolent course and normal-
ly responds well to treatment, with a tendency to com-
plete remission even with low doses of corticos-
teroids. Dapsone has been used with good results and
may be given as monotherapy or in combination with
systemic steroids. Immunosuppressants such as aza-
thioprine and cyclophosphamide can also be
used,4 especially in cases evolving to the classical
forms of pemphigus.13 The PH patients of our outpa-
tient dermatological clinic were treated with systemic
steroids (0,5-1,23 mg of prednisone) together with
dapsone. One patient, who presented with severe dis-
ease at the beginning, required pulse therapy with
methylprednisolone (1 g/day for 3 days) together
with azathioprine 150 mg/day (Figure 1). However,
effective control was achieved only after the introduc-
tion of dapsone, and all drugs were then gradually
discontinued without recurrence (Maehara Lde S et
al., unpublished data).
IGA PEMPHIGUS
IgA pemphigus was first described by Wallach,
Foldes, and Cottenot in 1982 under the name sub-
corneal pustular dermatosis and monoclonal IgA.47 It is
a group of autoimmune intraepidermal blistering dis-
eases presenting with a vesiculopustular eruption, neu-
trophil infiltration, acantholysis and tissue-bound and
circulating IgA antibodies targeting desmosomal or
nondesmosomal cell surface components in the epider-
mis.48 There are many synonyms for IgA pemphigus:
intraepidermal neutrophilic IgA dermatosis, intercellu-
lar IgA dermatosis, intercellular IgA vesiculopustular
dermatosis, intraepidermal IgA pustulosis, IgA pem-
phigus foliaceus, and IgA herpetiform pemphigus.47,49-57
EPIDEMIOLOGY
IgA pemphigus is a rare entity among the pem-
phigus diseases considering that only about 70 cases
were reported up to 2010.58 Its frequency is currently
not defined, and its race distribution is also unknown.
The sex distribution of IgA pemphigus reveals a male-
to-female ratio of 1:1.33.59 The age distribution is 1
month to 85 years old.4
CLINICAL FEATURES
The onset of IgA pemphigus is reported to be
subacute.59 There are two distinct types of IgA pemphi-
gus: the subcorneal pustular dermatosis (SPD) type and
the intraepidermal neutrophilic (IEN) type. Patients
with both types of IgA pemphigus clinically present
with flaccid vesicles or pustules on erythematous or
normal skin. The pustules tend to coalesce to form an
annular or circinate pattern with crusts in the central
area (Figure 2A and B). The SPD type shows clinical fea-
tures similar to those of SPD. The IEN type demon-
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strates a characteristic clinical feature, the so-called
“sunflower-like” configuration. A herpetiform appear-
ance has sometimes also been reported.54 The sites of
predilection are the axillary and groin areas, but the
trunk and proximal extremities are commonly involved.
About half of IgA pemphigus patients suffer from pru-
ritus, and mucous membrane involvement is rare.49,53,59,60
HISTOPATHOLOGY
Histopathologic examination of IgA pemphigus
shows slight acantholysis and neutrophilic infiltration
in the epidermis. Acantholysis in IgA pemphigus is
much milder than that seen in classic pemphigus.57 In
the SPD type of IgA pemphigus, pustules are located
subcorneally in the upper epidermis, whereas in the
IEN type, suprabasilar pustules in the lower or entire
epidermis are present. 49,53,61
IMMUNO-PATHOGENESIS
IgA deposition in the intercellular substance of
the epidermis is detected in all cases of IgA pemphigus
by DIF of perilesional skin, usually in a pattern similar
to pemphigus IgG deposition (Figure 2C).49,53-56,60,62 IgG or
complement component C3 is also sometimes deposit-
ed but is weaker than IgA.59 In the SPD type of IgA
pemphigus, IgA deposition is limited to the upper epi-
dermal cell surfaces , whereas in the IEN type of IgA
pemphigus, there is intercellular IgA deposition
restricted to the lower epidermis or throughout the
entire epidermis.54,60 IIF using patient sera and sub-
strates such as healthy human skin or monkey esopha-
gus shows the positive result in the cell-cell contact
region in the entire epidermis in about 50% of patients
(Figure 2D). The titers for autoantibodies are lower
than that in classic pemphigus.59 There are some reports
of cases with presence of both IgA and IgG antibodies,
which raises the question of whether pemphigus with
both IgG and IgA autoantibodies is a subset of IgA
pemphigus or not.63 The subclass of in vivo–bound and
circulating IgA autoantibodies has also been deter-
mined and is exclusively IgA1.49,55,61 Enzyme-linked
immunosorbent assay (ELISA) can be used for the
diagnosis of IgA pemphigus and for detection of
autoantibodies in individual patients.64
IgA pemphigus is a condition in which the IgA
reaction to the keratinocyte cell surfaces is thought to
be the leading pathogenic factor. The antigen of the
SPD type was identified as Dsc-1, whereas the antigen
of the IEN type is still unknown, although rare cases
showed IgA antibodies to either Dsg-1 or Dsg-3.65-
72 There is no clear explanation for the mechanism by
which IgA autoantibodies produce characteristic skin
lesions in IgA pemphigus. IgA autoantibodies might
bind to the Fc receptor CD89 on monocytes and gran-
ulocytes, resulting in accumulation of neutrophils and
subsequent proteolytic cleavage of the keratinocyte
cell–cell junction.73 The other issue to be considered is
the possible epitopespreading phenomenon, in which
an inflammatory event releases new target antigens,
exposes them to the immune system, and then induces
subsequent autoimmunity to new related antigens.74
ASSOCIATIONS
IgA pemphigus, particularly SPD-type, is
reported to be associated with malignancies, includ-
ing IgA gammopathy evolving into multiple myelo-
ma.75 In the cases reviewed by Wallach in 1992, six of
the 29 patients had an associated monoclonal gam-
mopathy of the IgA class, with k light chains in five of
the six patients. Two gammopathies were benign, one
patient had a B-cell lymphoma, and two patients had
myeloma. In two patients, the monoclonal gammopa-
thy developed only years after the onset of the der-
matosis.49 Other cases showed haematological malig-
FIGURE 2: IgA
Pemphigus (IEN
type): (A) and (B)
vesicles, blisters,
pustules and
crusts confluent,
occupying almost
the entire trunk,
neck and part of
the upper limbs;
(C) DIF: IgA
deposits intercel-
lular;(D) IIF sho-
wing presence of
IgA in the
patient´s sera
(1:640)
A B
D
C
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nancies including those of B-cell origin, while some
cases were associated with solid tumours, such as
lung cancer.76,77 Gastrointestinal diseases may also be
associated with IgA pemphigus: one case each of
Crohn’s disease and gluten-sensitive enteropathy
have been reported.49
TREATMENT
The small number of reported cases of IgA
pemphigus disrupts the analyses of its effective treat-
ments. The mainstays for treatment of IgA pemphigus
are oral and topical corticosteroids, owing to the
inflammatory nature of the disease.78 The suggested
corticosteroid dose is 0.5 to 1 mg/kg daily. In addi-
tion, dapsone usually at a dose of 100 mg daily may be
very useful in treating IgA pemphigus due to its effect
in suppressing neutrophilic infiltration.49,53,54,69,79,80
Isotretinoin and acitretin are also reported to be useful
for the treatment of IgA pemphigus.81,82 Recently,
mycophenolate mofetil and adalimumab, which are
known to be effective in classic pemphigus, are also
reported to be useful in treating IgA
pemphigus.83 Colchicine was also effective in one of
two patients and has also been used during the treat-
ment of one patient (IgA pemphigus, IEN type -Figure
2) of our outpatient dermatology clinic (university
hospital) with good results, together with systemic
steroids. Azathioprine, a commonly-used immuno-
suppressant in pemphigus, does not seem to be effec-
tive in treating IgA pemphigus.49 Aggressive therapy
with prednisone, cyclophosphamide and plasma-
pheresis has also been used for a recurrence after ini-
tial treatment with dapsone and prednisone.52
As a superficial blistering disease, IgA pemphi-
gus usually heals without scarring if appropriate treat-
ment is provided.59,61 Although clinical data for its prog-
nosis are still limited, the clinical presentation of IgA
pemphigus seems to be milder and the course more
benign than classic pemphigus. Recurrences of lesions
have been noted after termination of treatment or
reduction in drug dosage.55 In those cases with an asso-
ciated malignant IgA gammopathy, or other malignan-
cies, the prognosis was related to the malignancy.
PARANEOPLASTIC PEMPHIGUS
In 1990, Anhalt et al. described five atypical
pemphigus cases which were associated with lym-
phoproliferative disease. Anhalt called this disease
paraneoplastic pemphigus (PNP).84 The term paraneo-
plastic autoimmune multiorgan syndrome (PAMS)
was suggested later by Nguyen et al., given that is not
a skin disease, but a syndrome characterized by the
presence of mucocutaneous and non-cutaneous
pathology associated with neoplasia.85,86 In this article,
we adopt the term PNP for historical reasons.
DEFINITION AND EPIDEMIOLOGY
In the first description by Anhalt, PNP was
defined as a new mucocutaneous acantholytic disease
characterized by the presence of autoantibodies
(therefore named as pemphigus), in patients with neo-
plasia.84 These antibodies were shown to be pathogen-
ic after inoculation in mice.85,87
The exact incidence of PNP is not known. It is
a rare form of pemphigus: around 450 cases have been
reported in the literature.88 It predominates in men of
45 to 70 years of age.89 However, case reports of the
disease in children exist, and in them PNP has a
predilection for those of Hispanic origin.90 There is an
association with HLA class II DRB1*03  and HLA
Cw*14 in the Chinese population, different from
HLAs of risk for pemphigus vulgaris and
foliaceus (HLA DRB1*04 and DRB1*14).91,92
CLINICAL FEATURES
The typical initial manifestation is painful pro-
gressive stomatitis (Figures 3 and 4).93,94 Cutaneous
features of PNP are polymorphic, including vesicles,
blisters, erosions, patches, papules and plaques. The
Nikolsky sign may be absent.86 The symptoms include
the following:85 (I) pemphigus-like: superficial
vesicules, flaccid blisters, erosions and crusts, occa-
sional and limited erythema; (II) bullous pemphigoid-
like: scaling erythematous papules that may be associ-
ated or not wiht tense blisters; (III) erythema multi-
forme-like: polymorphic lesions, mainly scaling ery-
thematous papules with erosions or occasionally
ulcers with difficult healing; (IV) graft versus host dis-
ease-like: disseminated dusky red scaly papules; (V)
lichen planus-like: small squamous flat-topped vio-
laceus papules and intense involvement of mucosal
membranes (Figure 4).
PNP lesions affect not only the oral mucosa, but
also esophagus, stomach, duodenum, and
colon.95,96 Frequently, immunoglobulin and comple-
ment deposition in the pulmonary tissue is associated
with bronchiolitis obliterans, leading to respiratory
failure.97 Association of PNP with glomerulonephritis
and paraneoplastic neurological syndrome has also
been reported.98
Owing to the clinical variety of PNP cases, dif-
ferential diagnosis is suggested according to the pre-
dominance of the following clinical presentation:99 (I)
only oral lesions: PV, oral lichen planus, major apht-
hous stomatitis; (II) mucositis associated to lichenoid
lesions: lichen planus; (III) cutaneous and mucosal
lesions: erythema multiforme, toxic epidermal necrol-
ysis, pemphigus vulgaris.
Differentiation from PV may be difficult
because of the predominance of mucosal lesions.
Czernik et al.86 indicated characteristics for distinction:
An Bras Dermatol. 2014;89(1):96-117.
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FIGURE 3: Paraneoplastic pemphi-
gus: (A); ulcer in the side of the
tongue, organ typically affected in
paraneoplastic pemphigus. This
patient also had erosions in the
jugal mucosa and gingival enant-
hema. The diagnosis of an abdomi-
nal myofibroblastic tumor led to
the suspicion of PNP, which was
confirmed by indirect immuno-
fluorescence in rat bladder and
immunoblotting. The patient was
initially treated with prednisone
and azathioprine, and later, rituxi-
mab, with improvement; (B) DIF of
perilesional patient's skin showing
intercellular and basement mem-
brane zone staining (IgG, 10x); (C)
IIF in transitional epithelium: posi-
tive test for a patient with PNP (rat
bladder, 10x); (D) Immunoblotting
(left) and immunoprecipitation
(right): detection of antibodies
directed against periplakin (190
kd) and envoplakin (210 kd) is a
criterium for diagnosis
FIGURE 4: Paraneoplastic Pemphigus in patient presenting non-Hodgkin B-cell linfoma: (A) lesions affecting the lips and oral mucosa; (B) ero-
sions on the back; (C) blisters on the hands; (D)histopathology showing suprabasal blister containing acantholytic cells (HE 40x); (E) closer view
of the acantholytic cells and loss of intercellular cohesiveness (HE 400x); (F) DIF showing intercellular deposits of IgG and C3, and also linear
deposits in the BMZ (DIF, 400x); (G) IIF (rat bladder) showing intercellular distribution of anti-IgG (1:320)
A B
DC
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(I) in PV, there may be areas with healthy mucosa,
while PNP is characterized by diffuse involvement of
oral mucosa; (II) in PV, other mucosa such as conjunc-
tiva are rarely involved, though involvement of other
mucosa is more frequent in PNP; (III) in PV, palms
and soles are spared, which generally does not occur
in PNP; (IV) in PV, the scalp is frequently affected,
while in PNP the scalp is spared; (V) in PV, the
Nikolsky sign is present, however, this sign is absent
in PNP. Mortality in PV varies between 5 and 10%
with treatment, while it is much higher in PNP, inde-
pendent of therapy.97,100,101
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HISTOPATHOLOGY
The major histopathological feature of PNP is
vacuolar or lichenoid interface dermatitis
pattern.102 There may be intraepidermal cleft and acan-
tholysis, or more rarely, subepidermal blisters.86 The
clinical variants also have their respective histological
features:86 (I) pemphigus-like: intra-epidermal cleft
surrounded by mononuclear cells; (II) bullous pem-
phigoid-like: subepidermal cleft with or without basal
cellular vacuolization, and moderate mononuclear
infiltrate in dermo-epidermal junctions; (III) erythe-
ma multiforme-like: dyskeratosis without cleft or with
areas of epidermal separation, due to basal cell disin-
tegration, and distinct perivascular infiltrate; (IV)
graft  versus host disease-like: absence of epidermal
separation, hyperkeratosis or hyperparakeratosis and
dyskeratosis with or without vacuolar degeneration
of basal cell layers and intense mononuclear interface
dermatitis; (V) lichen planus-like: hypergranulosis,
dyskeratosis and lichenoid mononuclear infiltrate.
This range of variations in clinical and histolog-
ical features is due to the different mechanisms of
pathogeny in PNP: it may be a B-cell mediated disease
like pemphigus or a T-cell mediated disease like
lichen planus.85
IMMUNOPATHOGENESIS
Although the origin of the disease is unclear, it
is speculated that the immune response in PNP may
have two origins:  (I) immune response to neoplastic
antigens with autoantibodies that cross-react to
epithelial antigens, or (II) tumors which either synthe-
size pathogenic autoantibodies or deregulate the
immune system by synthesizing cytokines, such as
IL6, which promotes B-cell differentiation and levels
of which are elevated in PNP and in Castleman’s dis-
ease, leading to an autoimmune response.99,103
ASSOCIATIONS
According to the definition based on the first
cases, PNP is associated with neoplasia, and rare cases
are described in which neoplasia was not identified.84
Three neoplasias are commonly associated with PNP:
non-Hodgkin’s lymphoma (42%), chronic lymphocyt-
ic leukemia (29%) and Castleman’s disease (10%)
(Figure 4). Other neoplasias described were thymo-
mas (6%), sarcomas (6%) and Waldenstrom’s
macroglobulinemia (6%).99 In children, Castleman’s
disease is the leading associated neoplasia.90
DIAGNOSTIC CRITERIA
In 1990, Anhalt initially proposed five criteria for
the definition of a PNP case: (1) painful mucosal ero-
sions and polymorphous skin eruption in the context of
a neoplasia; (2) histological changes (acantholysis, ker-
atinocyte necrosis, interface dermatitis); (3) DIF show-
ing IgG and complement deposition in intercellular
substance and basement membrane zone; (4) IIF with
the same deposition as for DIF, in skin, mucosa and
simple, columnar, and transitional epithelium and (5)
demonstration of serum antibodies through immuno-
precipitation of a complex of four keratinocyte proteins
(250, 230, 210 e 190 kd) (Figures 3 and 4).84
Subsequently, many authors proposed similar
diagnostic criteria for PNP.88,99,101 In 2004, Anhalt pro-
posed minimal diagnostic criteria for PNP.99 (1) clini-
cal: painful progressive stomatitis with preferential
involvement of tongue; (2) histological: acantholysis
or interface dermatitis; (3) immunological: presence of
antiplakin antibodies (at least periplakin and envo-
plakin). The pivotal criterium of PNP is autoantibod-
ies directed against desmosomal plakin proteins:
desmoplakin I (250 kDa), desmoplakin II (210 kDa),
envoplakin (210 kDa), periplakin (190kDa), and  α2-
macroglobulin-like-1 protein (170 kDa). In addition,
autoantibodies against Dsg-1, Dsg-3, plectin and 230-
kDa bullous pemphigoid antigen can be
detected.104 These antiplakin antibodies should be
revealed by immunoprecipitation or immunoblotting,
in addition to positive IIF in monkey esophagus and
rat bladder (Figure 3). Anti-Dsg-3 ELISA may also be
positive – but this does not discriminate between PNP
and other pemphigus variants (PV and PF). (4)
Association with lymphoproliferative disorder: non-
Hodgkin’s lymphoma and chronic lymphocytic
leukemia generally in cases with previous diagnosis
(2/3 of cases), and Castleman’s disease, abdominal
lymphoma, thymomas or retroperitoneal sarcoma in
cases with ocult neoplasia at the time of diagnosis of
PNP (1/3 of cases).99
TREATMENT
Patients with a diagnosis of PNP without previ-
ous diagnosis of a neoplasia – about 17% of PNP cases –
must be investigated with complete blood count with
differential leukocyte, serum protein electrophoresis,
computerized tomography (chest, abdomen, and
pelvis), and biopsies of bone marrow, lymph nodes, or
solid tumor, according to indication.86, 101
The most widely suggested specific treatment
combines prednisone (0.5-1.0 mg/kg) with
cyclosporine (5 mg/kg), and may also include
cyclophosphamide (2 mg/kg). However, the disease
is generally resistant to therapy.99,105 The mortality of
patients with PNP is 75% to 90%.101 Respiratory failure
due to bronchiolitis obliterans is one of the most
important causes of death in patients with
PNP/PAMS.85,97,99 However, a recent study, conducted
in France, has made a valuable contribution to evalu-
Revista1Vol89ingles_Layout 1  2/11/14  3:21 PM  Página 102
An Bras Dermatol. 2014;89(1):96-117.
Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus,... 103
ating the prognosis of PNP.101 The authors analysed
patients from 27 different medical centers, demon-
strating that the disease course is highly variable, not
only in severe cases, but also in indolent disease, and
that prognosis is worst in the presence of erythema
multiforme-like lesions and of necrotic keratinocytes
in histopathological exam. The conclusion of this
study was a mortality of 51%, 59% and 69% in 1, 2 and
5 years, respectively. The lower mortality than previ-
ously found might be due to the inclusion of less
severe cases due to a lower threshold, since diagnosis
was made if 4 of the 7 criteria were met. These 7 crite-
ria were based on the 5 criteria of Anhalt, adding the
presence of neoplasia and indirect immunofluores-
cence in human skin as independent criteria.84
Rituximab may be indicated, especially because
of association with non-Hodgkin’s lymphoma,
though there are reports of complications and low
therapeutic response.105,106
In general, treatment of neoplasia is not associ-
ated with improvement of PNP, except in cases associ-
ated to Castleman’s disease.107-109 Tumor resection or
complete response to neoplasia treatment does not
alter the progression of respiratory disease, although
mucocutaneous lesions may heal.110 Pulmonary dis-
ease, when present, is irreversible.85,86,99 Although the
complete mechanism of bronchiolitis obliterans is not
elucidated, several authors have studied the charac-
teristics of pulmonary disease, which might con-
tribute for future therapy.97,111,112
IGG/ IGA PEMPHIGUS
Over the past thirty years, some atypical and
typical cases of pemphigus have been described with
the name IgG/ IgA pemphigus. In most of them an
intercellular pattern of IgG and IgA (and sometimes
also C3) was seen in the DIF. Nishikawa et al probably
were the first to report in 1987, when they described
an atypical PF case during the XVII World Congress of
Dermatology.113 Since then we have found another 14
similar case reports.114-126 Two other articles that stud-
ied the frequency of IgA antibodies in different bul-
lous diseases127 and the autoantigens recognized by
IgA anti-keratinocyte cell surface antibodies    both
describe another six not previously reported cases
presenting with intercellular IgG and IgA in the DIF.60
Three other cases were also called IgG/ IgA pemphi-
gus, despite presenting negative DIF128 or only inter-
cellular IgG by DIF (but both intercellular IgG and
IgA by IIF)  or only intercellular IgA by DIF (but both
intercellular IgG and IgA by IIF).63,129 Two of these
cases differ from all of the others by also showing
IgG63 or IgG and IgA in the BMZ by DIF.124
DEFINITION AND EPIDEMIOLOGY
There appears to be no consensus on whether
this is a unique form of pemphigus. Considering the
previous reports, this form could be defined as a case
showing IgG and IgA intercellular deposits in the DIF
studies and/or IIF, showing clinical and histologic
features that can resemble PF, PV, PH or IgA pemphi-
gus or that does not look like any of these forms (atyp-
ical). The age of the patients from the reports ranged
from 11 to 81 years. A Tunisian study found only one
case of IgG/ IgA pemphigus among the 92 pemphigus
patients evaluated during an 11-year period.130
However a recent study brings casts doubt on
whether this is really a unique entity. Mentink et
al  tested the sera of 100 cases of pemphigus patients
(34 PF, 58 PV and 8 PNP) in both anti-Dsg-1 and 3 IgA
ELISA tests and 54 sera were found to have IgA to one
or both Dsgs.131 They also found that more than half of
the cases that showed IgA anti-Dsg in the ELISA pre-
sented negative staining for IgA in IIF and/or DIF.
The ELISA thereby seems a more sensitive assay than
IIF analysis for detecting anti-Dsg IgA antibodies.
Thus they concluded that, in a considerable number of
supposedly IgG mediated pemphigus patients, IgA to
Dsg-1 and Dsg-3 is also present and proposed that a
spectrum with increasing IgA contribution may exist,
ranging from the pure classical IgG forms via mixed
IgG/IgA forms to pemphigus types with only IgA
against Dsgs.
CLINICAL FEATURES
The clinical features of the reported cases are
heterogeneous: PF- like,  PV- like,  PH-like,  IgA pem-
phigus-like,   or atypical/mixed cases.60,63,72,114-131
Pruritus, pustules and annular lesions are present in
almost half of the cases. Most of them do not show
mucous lesions.
HISTOPATHOLOGY
The reported cases also show multiple histolog-
ical features, with acantholysis in almost half of them.
The level of cleavage varies from subcorneal and
intraepidermal (the most common pattern) to
suprabasal bulla. Neutrophilic exocytosis is present in
the majority of the reports, sometimes together with
eosinophils and/ or spongiosis.
IMMUNO-PATHOGENESIS
The case reports usually show IgG and IgA
intercellular deposits in the DIF and/or IIF studies.
Two cases deserve special note for also showing
IgG  or IgG and IgA  in the BMZ by DIF: both present-
ed with cutaneous and mucous lesions and subepi-
dermal cleavage and were extensive investigated to
exclude the possibility of malignancy.63,124
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The cases are also heterogeneous concerning
the target antigens: Dsg-1,  Dsg-3, Dsc-1,  Dsc-2,  Dsc-
3, and Desmoplakin 1 and 2.60,63,72,114-129
ASSOCIATIONS
The minority of cases were associated with
other diseases: IgA-lambda monoclonal gammopa-
thy, malignancy (lung cancer, ovarian carcinoma, car-
cinoma of the gall bladder and adenocarcinoma of the
pancreas ), benign liver cyst and ovarian tumour, gas-
tric ulcers,    positive lupus anticoagulant IgM and
increased anticardiolipin antibody  and antihyperten-
sive drug use.116-119,121-123,125,126 However, it is not clear if
those are merely sporadic associations.
TREATMENT
Most of the reported cases showed good
response to dapsone, with or without systemic corti-
costeroids or to topical or systemic steroids alone.
Other immunosuppressant drugs were required only
in one case. Other drugs employed were acitretin, anti-
malarial and nicotinamide and minocycline.116,122,123, 124
CONCLUSION
This article has reviewed the knowledge about
the nonclassical forms of pemphigus. Future research
on the patho-physiology and the role of the target
antigens may help to answer some questions that are
still not clear, especially concerning the proper posi-
tion of pemphigus herpetiformis and IgG/ IgA pem-
phigus in the pemphigus group.
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